RNA, U4 small nuclear 52, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU4-52P profile across patient tissues and cancer cell-line models. RNU4-52P expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RNU4-52P is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, RNU4-52P RNA expression shows 14,918 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, BLCA, and UVM as cancer lineages where RNU4-52P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU4-52P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU4-52P survival associations across molecular data types. RNU4-52P RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU4-52P RNA expression–survival associations across cancer types. High RNU4-52P expression shows unfavorable associations in KIRC, LGG and ESCA, but favorable associations in HNSC, MESO and READ. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for RNU4-52P RNA expression.
This table summarizes RNU4-52P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU4-52P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU4-52P shows lower tumor expression in BRCA and higher tumor expression in BLCA, LIHC, LUSC, PAAD and LUAD. The BLCA box plot shows higher RNU4-52P RNA expression in tumor versus normal tissue (log2 FC = +1.381, t-test p < 0.001).
This table shows molecular features associated with RNU4-52P in patient tissues and cancer cell lines. In patient samples, RNU4-52P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
